Skip to search formSkip to main contentSkip to account menu

Open Label Study

Known as: OPEN LABEL 
A type of study that stipulates both the health provider and the subject be aware of the drug or treatment assignment.
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM Trial Blinding Schema TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Multinutrients for ADHD Youth (MADDY) Trial: Preliminary Trends for Treatment (P16-028-19).
Objectives Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder with increasing global prevalence and… 
2018
2018
IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive…
Background TAF has shown less bone and renal effects with similar efficacy rates compared to TDF in Phase 3 studies after 96… 
Review
2017
Review
2017
THU0110 The importance of sustained remission for longterm outcomes in patients with rheumatoid arthritis
Background In patients (pts) with rheumatoid arthritis (RA), the long-term impact of sustained versus (vs) transient clinical… 
2016
2016
Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
Abstract Objective: To evaluate measures of sleep (exploratory endpoints) in two pivotal studies of a multilayer bead extended… 
Review
2016
Review
2016
AB0315 Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis
Background In rheumatoid arthritis (RA) patients (pts) receiving corticosteroids (CS) or methotrexate (MTX) with an anti-TNF… 
2015
2015
Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
2011
2011
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment. To examine long-term… 
2004
2004
A predictive model of hospitalization and potential cost savings associated with oxandrolone in cancer patients with involuntary weight loss (IWL).
8259 Background: Patients (pts) with cancer often experience IWL. Health economics literature is limited and has focused on… 
1997
1997
Effects of nandrolone decanoate (ND) on nitrogen balance, metabolism, body composition and function in men with AIDS wasting syndrome (AWS)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)